News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
People taking statin drugs to lower their cholesterol may slightly increase their risk for muscle and joint diseases as well as strains and sprains, a new study suggests.The results were published online June 3 in the journal JAMA Internal Medicine.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
Rosuvastatin 10 mg, Fenofibrate 160 mg Tablets
 
  COMPOSITION:  
  Rosuvastatin 10 mg, Fenofibrate 160 mg  
     
  THERAPEUTIC INDICATIONS:  
 
Treatment of Gastro-oesophageal reflux disease, Prophylaxis of NSAID-induced ulcers, H.pylori infection,  Prophylaxis of migraine, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Reconstitution
 
     
  DOSAGE AND ADMINISTRATION:  
 
Normal release prep: May be taken with or without food. Admin instructions for modified release prep may vary according to brands, refer to lit.
Oral

Gastro-oesophageal reflux disease
Adult: 20-40 mg once daily in the morning for 4 wk, increased to 8 wk if necessary. Maintenance: 20-40 mg daily, increased to 40 mg each morning if symptoms return.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients. 
Oral
Peptic ulcer
Adult: 40 mg once daily in the morning for 2-4 wk for duodenal ulceration or 4-8 wk for benign gastric ulceration.
Hepatic impairmentDoses >40 mg daily have not been studied in hepatically-impaired patients. 
Oral
H.pylori infection
Adult: Triple therapy: 40 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid.
Hepatic impairmentDoses >40 mg daily have not been studied in hepatically-impaired patients. 
Oral
Prophylaxis of NSAID-induced ulcers
Adult: 20 mg daily.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients. 
Oral
Zollinger-Ellison syndrome
Adult: Initially 80 mg daily, adjusted to individual requirements. Up to 240 mg daily may be used if needed. Daily doses >80 mg should be given in 2 divided doses. 
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients. 
Intravenous
Zollinger-Ellison syndrome
Adult: As Na salt: 80 mg once or twice daily. Up to 240 mg daily may be given in divided doses. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes. 
Hepatic impairment: May need to reduce dose. 
Intravenous
Gastro-oesophageal reflux disease
Adult: As Na salt: 40 mg daily. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes. 
Hepatic impairment: May need to reduce doses. 
Intravenous
Peptic ulcer
Adult: As Na salt: 40 mg daily. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes. 
Hepatic impairment: May need to reduce doses.
Special Populations: Reduce dose in patients with severe hepatic impairment or give only on alternate days. Max dose: 20 mg daily or 40 mg on alternate days.
Reconstitution: Reconstitute with 10 ml 0.9% sodium chloride (final concentration 4 mg/ml). Reconstituted solution may be given IV (over 2 minutes) or diluted to 100 ml in glucose 5%, 0.9% sodium chloride, or lactated Ringer's and infused over 15 min.
Incompatibility: Y site incompatibility: midazolam and zinc.
 
     
  CONTRAINDICATIONS :  
  Lactation.  
     
  WARNINGS & PRECAUTIONS:  
 
Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment; monitor liver function regularly (if enzymes increase, discontinue); pregnancy; not recommended in children <18 yr; long term use may lead to atrophic gastritis
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints